Which has higher earnings and valuation, CMPS or IMVT?

Immunovant is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compass Pathways N/A N/A -$287.86M -$3.15 N/A Immunovant N/A N/A -$505.61M -$2.78 N/A

Is CMPS or IMVT more profitable?

Compass Pathways' return on equity of -31.07% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Compass Pathways N/A -31.07% -11.40% Immunovant N/A -65.66% -59.88%

Does the media favor CMPS or IMVT?

In the previous week, Immunovant had 9 more articles in the media than Compass Pathways. MarketBeat recorded 13 mentions for Immunovant and 4 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.58 beat Immunovant's score of -0.29 indicating that Compass Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 1 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CMPS or PTGX?

In the previous week, Protagonist Therapeutics had 7 more articles in the media than Compass Pathways. MarketBeat recorded 11 mentions for Protagonist Therapeutics and 4 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.58 beat Protagonist Therapeutics' score of 0.39 indicating that Compass Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, CMPS or ABVX?

Abivax is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compass Pathways N/A N/A -$287.86M -$3.15 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is CMPS or ABVX more profitable?

Compass Pathways' return on equity of -31.07% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Compass Pathways N/A -31.07% -11.40% Abivax N/A -99.02% -70.26%

Does the media prefer CMPS or ABVX?

In the previous week, Abivax had 12 more articles in the media than Compass Pathways. MarketBeat recorded 16 mentions for Abivax and 4 mentions for Compass Pathways. Abivax's average media sentiment score of 0.95 beat Compass Pathways' score of 0.58 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CMPS or SYRE more profitable?

Compass Pathways' return on equity of -31.07% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Compass Pathways N/A -31.07% -11.40% Spyre Therapeutics N/A -42.88% -27.76%

Does the media prefer CMPS or SYRE?

In the previous week, Spyre Therapeutics had 4 more articles in the media than Compass Pathways. MarketBeat recorded 8 mentions for Spyre Therapeutics and 4 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.58 beat Spyre Therapeutics' score of 0.42 indicating that Compass Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CMPS or MIRM?

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Compass Pathways. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 4 mentions for Compass Pathways. Mirum Pharmaceuticals' average media sentiment score of 0.97 beat Compass Pathways' score of 0.58 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Compass Pathways (CMPS) Competitors

$14.15 -0.92 (-6.10%)

Closing price 04:00 PM Eastern

Extended Trading

$14.23 +0.08 (+0.57%)

As of 07:59 PM Eastern

Compare

CMPS vs. IMVT, PTGX, ABVX, SYRE, and MIRM

Should you buy Compass Pathways stock or one of its competitors? MarketBeat compares Compass Pathways with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Compass Pathways include Immunovant (IMVT), Protagonist Therapeutics (PTGX), Abivax (ABVX), Spyre Therapeutics (SYRE), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

How does Compass Pathways compare to Immunovant?

Compass Pathways (NASDAQ:CMPS) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Compass Pathways' return on equity of -31.07% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Immunovant	N/A	-65.66%	-59.88%

In the previous week, Immunovant had 9 more articles in the media than Compass Pathways. MarketBeat recorded 13 mentions for Immunovant and 4 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.58 beat Immunovant's score of -0.29 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	1 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compass Pathways has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

46.2% of Compass Pathways shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Immunovant is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Compass Pathways currently has a consensus price target of $23.10, indicating a potential upside of 63.25%. Immunovant has a consensus price target of $39.70, indicating a potential upside of 2.98%. Given Compass Pathways' stronger consensus rating and higher possible upside, equities analysts clearly believe Compass Pathways is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Summary

Compass Pathways beats Immunovant on 11 of the 14 factors compared between the two stocks.

How does Compass Pathways compare to Protagonist Therapeutics?

Compass Pathways (NASDAQ:CMPS) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

In the previous week, Protagonist Therapeutics had 7 more articles in the media than Compass Pathways. MarketBeat recorded 11 mentions for Protagonist Therapeutics and 4 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.58 beat Protagonist Therapeutics' score of 0.39 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compass Pathways has a beta of 2.5, meaning that its stock price is 150% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market.

Compass Pathways has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Compass Pathways currently has a consensus target price of $23.10, indicating a potential upside of 63.25%. Protagonist Therapeutics has a consensus target price of $115.21, indicating a potential downside of 6.01%. Given Compass Pathways' stronger consensus rating and higher probable upside, equities analysts clearly believe Compass Pathways is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Protagonist Therapeutics has higher revenue and earnings than Compass Pathways. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Protagonist Therapeutics	$46.02M	171.30	-$130.15M	-$1.81	N/A

46.2% of Compass Pathways shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Compass Pathways and Protagonist Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Compass Pathways compare to Abivax?

Compass Pathways (NASDAQ:CMPS) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Compass Pathways' return on equity of -31.07% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Abivax	N/A	-99.02%	-70.26%

Abivax is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

46.2% of Compass Pathways shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Compass Pathways has a beta of 2.5, meaning that its share price is 150% more volatile than the broader market. Comparatively, Abivax has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Compass Pathways currently has a consensus price target of $23.10, indicating a potential upside of 63.25%. Abivax has a consensus price target of $144.46, indicating a potential upside of 8.37%. Given Compass Pathways' stronger consensus rating and higher probable upside, equities research analysts plainly believe Compass Pathways is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Abivax	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

In the previous week, Abivax had 12 more articles in the media than Compass Pathways. MarketBeat recorded 16 mentions for Abivax and 4 mentions for Compass Pathways. Abivax's average media sentiment score of 0.95 beat Compass Pathways' score of 0.58 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compass Pathways beats Abivax on 10 of the 14 factors compared between the two stocks.

How does Compass Pathways compare to Spyre Therapeutics?

Compass Pathways (NASDAQ:CMPS) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

46.2% of Compass Pathways shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Spyre Therapeutics had 4 more articles in the media than Compass Pathways. MarketBeat recorded 8 mentions for Spyre Therapeutics and 4 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.58 beat Spyre Therapeutics' score of 0.42 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compass Pathways has a beta of 2.5, meaning that its share price is 150% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.05, meaning that its share price is 205% more volatile than the broader market.

Compass Pathways' return on equity of -31.07% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Spyre Therapeutics has higher revenue and earnings than Compass Pathways. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Spyre Therapeutics	$890K	8,772.26	-$155.20M	-$2.08	N/A

Compass Pathways presently has a consensus target price of $23.10, indicating a potential upside of 63.25%. Spyre Therapeutics has a consensus target price of $95.83, indicating a potential upside of 7.94%. Given Compass Pathways' higher possible upside, equities research analysts clearly believe Compass Pathways is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Spyre Therapeutics beats Compass Pathways on 7 of the 12 factors compared between the two stocks.

How does Compass Pathways compare to Mirum Pharmaceuticals?

Compass Pathways (NASDAQ:CMPS) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Compass Pathways presently has a consensus price target of $23.10, indicating a potential upside of 63.25%. Mirum Pharmaceuticals has a consensus price target of $139.80, indicating a potential upside of 19.37%. Given Compass Pathways' stronger consensus rating and higher possible upside, equities analysts plainly believe Compass Pathways is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Compass Pathways has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Compass Pathways has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

46.2% of Compass Pathways shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Mirum Pharmaceuticals has higher revenue and earnings than Compass Pathways. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Mirum Pharmaceuticals	$521.31M	13.70	-$23.36M	-$13.61	N/A

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Compass Pathways. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 4 mentions for Compass Pathways. Mirum Pharmaceuticals' average media sentiment score of 0.97 beat Compass Pathways' score of 0.58 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compass Pathways and Mirum Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Compass Pathways News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMPS vs. The Competition

Export

Metric	Compass Pathways	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.03B	$9.35B	$7.07B	$12.45B
Dividend Yield	N/A	1.66%	2.66%	6.16%
P/E Ratio	-4.49	26.17	27.51	24.87
Price / Sales	N/A	17.10	540.69	102.84
Price / Cash	N/A	114.51	48.53	58.59
Price / Book	-25.73	5.95	11.01	6.54
Net Income	-$287.86M	$179.69M	$3.57B	$336.70M
7 Day Performance	11.86%	4.90%	2.56%	3.31%
1 Month Performance	8.35%	4.51%	0.89%	1.68%
1 Year Performance	405.36%	14.87%	36.84%	31.96%

Compass Pathways Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMPS Compass Pathways	2.8211 of 5 stars	$14.15 -6.1%	$23.10 +63.3%	+444.0%	$2.03B	N/A	N/A	120
IMVT Immunovant	1.249 of 5 stars	$38.51 -0.9%	$37.33 -3.1%	+139.2%	$7.98B	N/A	N/A	120	Analyst Forecast
PTGX Protagonist Therapeutics	0.9674 of 5 stars	$121.63 -0.2%	$115.21 -5.3%	+118.4%	$7.84B	$46.02M	N/A	120	Analyst Downgrade
ABVX Abivax	1.9624 of 5 stars	$96.15 -1.4%	$130.08 +35.3%	+1,199.3%	$7.78B	N/A	N/A	61	Trending News Analyst Forecast Gap Up
SYRE Spyre Therapeutics	1.7202 of 5 stars	$90.16 +2.6%	$95.83 +6.3%	+492.4%	$7.63B	$890K	N/A	73	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMPS) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compass Pathways (CMPS) Competitors

CMPS vs. IMVT, PTGX, ABVX, SYRE, and MIRM

How does Compass Pathways compare to Immunovant?

Summary

How does Compass Pathways compare to Protagonist Therapeutics?

Summary

How does Compass Pathways compare to Abivax?

Summary

How does Compass Pathways compare to Spyre Therapeutics?

Summary

How does Compass Pathways compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS vs. The Competition

Compass Pathways Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compass Pathways (CMPS) Competitors

CMPS vs. IMVT, PTGX, ABVX, SYRE, and MIRM

How does Compass Pathways compare to Immunovant?

Is CMPS or IMVT more profitable?

Does the media favor CMPS or IMVT?

Which has more volatility & risk, CMPS or IMVT?

Do insiders and institutionals believe in CMPS or IMVT?

Which has higher earnings and valuation, CMPS or IMVT?

Do analysts recommend CMPS or IMVT?

Summary

How does Compass Pathways compare to Protagonist Therapeutics?

Does the media prefer CMPS or PTGX?

Which has more volatility & risk, CMPS or PTGX?

Is CMPS or PTGX more profitable?

Do analysts rate CMPS or PTGX?

Which has higher valuation & earnings, CMPS or PTGX?

Do insiders & institutionals believe in CMPS or PTGX?

Summary

How does Compass Pathways compare to Abivax?

Is CMPS or ABVX more profitable?

Which has higher earnings and valuation, CMPS or ABVX?

Do insiders & institutionals have more ownership in CMPS or ABVX?

Which has more risk & volatility, CMPS or ABVX?

Do analysts rate CMPS or ABVX?

Does the media prefer CMPS or ABVX?

Summary

How does Compass Pathways compare to Spyre Therapeutics?

Do institutionals and insiders have more ownership in CMPS or SYRE?

Does the media prefer CMPS or SYRE?

Which has more risk and volatility, CMPS or SYRE?

Is CMPS or SYRE more profitable?

Which has preferable earnings & valuation, CMPS or SYRE?

Do analysts rate CMPS or SYRE?

Summary

How does Compass Pathways compare to Mirum Pharmaceuticals?

Do analysts rate CMPS or MIRM?

Which has more risk & volatility, CMPS or MIRM?

Is CMPS or MIRM more profitable?

Do institutionals & insiders believe in CMPS or MIRM?

Which has preferable earnings & valuation, CMPS or MIRM?

Does the media refer more to CMPS or MIRM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS vs. The Competition

Compass Pathways Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools